ClinicalTrials.gg
CompletedNCT07712536Updated Jul 17, 2026

Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of QY201 Tablets(10mg) and QY201 Tablets(20mg) in Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD), sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.. Completed at 1 site in China. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jun 2025, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
173rd of 190
24 · median 164
Started
2025
with 33 others
Phase 2
58 of 206
16 open now
Registered
196th of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 173rd largest by enrollment of the 190 interventional ones that give a count, is one of 34 that started in 2025, is one of 58 in phase 2, and was the 196th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

To evaluate the population pharmacokinetic characteristics of QY201 Tablets in adolescent participants with moderate to severe atopic dermatitis (AD).

03

Conditions studied

  • Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)

Browse trials for

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant and their parent/legal guardian (if applicable) shall have effective communication with the investigator, fully understand the purpose, nature, methods and potential adverse reactions of this trial, comprehend and comply with all requirements of the study, and sign the Form (ICF) prior to initiation of any study procedures.
  2. Age ≥12 years and \<18 years (calculated based on the date of ICF signature), any gender, body weight ≥40 kg.
  3. Has a documented history of atopic dermatitis (AD) for at least 6 months at screening, and meets the Hanifin-Rajka diagnostic criteria at screening.
  4. Meets criteria for moderate to severe AD at screening and baseline:

    Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) score ≥3 at screening and baseline; Eczema Area and Severity Index (EASI) score ≥16 at screening and baseline; Body Surface Area (BSA) affected by AD ≥10% at screening and baseline; Weekly average of daily Pruritus Numerical Rating Scale (PP-NRS) score ≥4 at baseline.

  5. Within 6 months prior to screening, documented evidence of inadequate response to or intolerance of topical therapies including topical (TCS) and/or topical calcineurin inhibitors (TCI); or documented indication for systemic therapy (e.g., systemic corticosteroids, conventional , biologics, JAK inhibitors, etc.) for disease control.
  6. The participant is able and willing to regularly apply fragrance-free and inactive-ingredient-free emollients twice daily for at least 7 consecutive days prior to randomization, and continue such application throughout the study period.
  7. Participants of (females post-menarche, males post-spermarche) must agree to and implement effective from the date of ICF signature through 3 months after the last study drug administration. For female participants of childbearing potential, serum human chorionic gonadotropin (HCG) test shall be negative at screening, and the subject must not be breastfeeding.

Exclusion criteria

Exclusion Criteria:

  1. Receipt of the following therapies within 12 weeks prior to baseline (or 5 half-lives, whichever is longer):

    Small-molecule targeted drugs: Janus kinase (JAK) inhibitors (e.g., Ruxolitinib, Tofacitinib, Baricitinib, Upadacitinib, Abrocitinib), etc.; Macromolecular biologics: e.g., Dupilumab, Spesolimab, etc.

  2. Receipt of the following systemic therapies within 4 weeks prior to baseline (or 5 half-lives, whichever is longer):

    Systemic /immunomodulatory agents (e.g., systemic , cyclosporine, mycophenolate mofetil, interferon gamma, azathioprine, methotrexate, etc.); Phototherapy (e.g., ultraviolet B [UVB], psoralen plus ultraviolet A [PUVA], etc.), including indoor tanning; Systemic Chinese herbal medicines or proprietary Chinese medicines; Other systemic medications for the treatment of atopic dermatitis (AD).

  3. Receipt of the following topical therapies within 2 weeks prior to baseline:

    Topical corticosteroids (TCS); Topical calcineurin inhibitors (TCI); Topical phosphodiesterase 4 (PDE-4) inhibitors; Topical Chinese herbal preparations or herbal medicated baths; Other topical medications for the treatment of AD.

  4. Receipt of allergen-specific immunotherapy within 6 months prior to baseline.
  5. Use of strong inhibitors or strong inducers of cytochrome P450 3A () hepatic metabolic enzymes within 2 weeks prior to baseline.
  6. Use of long-acting anticoagulants (e.g., warfarin, clopidogrel, etc.) within 4 weeks prior to baseline, or requirement for continuous anticoagulant therapy (excluding aspirin at a dose ≤100 mg per day).
  7. Planned administration of live or attenuated within 4 weeks prior to baseline; or anticipated need for live or attenuated live vaccines during the study period (including at least 4 weeks after the last dose of product).
  8. Participation in any clinical trial involving an investigational product within 4 weeks prior to baseline (or 5 half-lives, whichever is longer), or participation in any clinical trial involving a medical device within 3 months prior to baseline.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    QY201 Tablets(10mg)

    10 mg twice daily for 28 consecutive days

    Drug: QY201 Tablets(10mg)

  • Experimental
    QY201 Tablets(20mg)

    20 mg twice daily for 28 consecutive days

    Drug: QY201 Tablets(20mg)

Interventions

  • DrugQY201 Tablets(10mg)

    10 mg twice daily for 28 consecutive days

  • DrugQY201 Tablets(20mg)

    20 mg twice daily for 28 consecutive days

06

What researchers measure

Primary outcomes

  1. Plasma concentrations of QY201 at multiple time points; population pharmacokinetic (PopPK) profiles of QY201

    Time frame: Day29

07

Study locations

1 site
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang 310000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Dec 2025, 6 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 6 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 17, 2026
StartActual
Jun 4, 2025
Primary completionActual
Dec 19, 2025
CompletionActual
Dec 19, 2025
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07712536
Lead sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Jun 4, 2025
Primary completion
Dec 19, 2025
Completion
Dec 19, 2025
Last update
Jul 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion